Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 11 Best Stocks to Buy for Investment.

On January 11, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) unveiled its new five-year strategy, ‘Alnylam 2030.’ The company shared its plans to scale operations, focus on durable leadership in transthyretin (TTR) amyloidosis, and deliver sustained, profitable growth.

Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy

Alnylam Pharmaceuticals is targeting to lead the global TTR market and generate revenue through 2030. TTR is a protein disorder that starts building irregular proteins known as fibrils in your heart, making it hard for the heart to pump blood to the body. The company plans to launch next-generation RNAi silencer nucresiran in polyneuropathy by 2028 and cardiomyopathy by 2030. In addition to other research and product goals, the company aims to achieve a revenue CAGR of over 25% through 2030 and to reach a non-GAAP operating margin of nearly 30%.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) projects its 2026 combined net product revenue to be between $4.9 billion and $5.3 billion. The majority of the revenue is expected from TTR, while the Rare segment revenue is expected to be around $500-$600 million. On January 12, TheFly reported that Needham analyst Joseph Stringer increased the price target on Alnylam Pharmaceuticals from $520 to $529, keeping a Buy rating. Stringer remains positive on ALNY following the company’s promising FY2026 outlook. The analyst sees Alnylam’s Amvuttra launch in TTR-CM to be a major catalyst for the stock in 2026, citing that the initial revenue guidance looks highly encouraging and has additional room for upside.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biotech firm that discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. The company’s core focus is to develop transformative therapies to prevent or reverse disease.

While we acknowledge the potential of ALNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALNY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best New Penny Stocks to Invest In and 13 Best Gold Mining Companies to Invest In Now.

Disclosure: None. This article is originally published at Insider Monkey.